Yıl: 2015 Cilt: 50 Sayı: 2 Sayfa Aralığı: 73 - 82 Metin Dili: Türkçe

Hemolitik üremik sendrom

Öz:
Hemolitik üremik sendrom (HÜS) mikroanjiopatik hemolitik anemi, trombositopeni ve akut böbrek hasarı üçlüsü ile tanımlanan bir klinik tablodur. Hemolitik üremik sendrom etiyolojileri, seyirleri ve tedavi yaklaşımları farklı olan bir grup hastalıktan oluşur. Son yıllarda HÜSe yol açan hastalıkların daha iyi anlaşılması, özellikle kompleman ilişkili HÜS olgularında genetik mutasyonların gösterilmesi hastalığa ait tanımlar, sı- nıflamalar ve tedavi yaklaşımlarında güncellemelere neden olmuştur. Bu yazıda hastalığın güncel sınıflaması, çocukluk çağındaki HÜSün en sık nedeni olan STEC-HÜS ve yeni tanı ve tedavi yaklaşımları ile kompleman ilişkili HÜS anlatılacaktır.
Anahtar Kelime:

Hemolytic uremic syndrome

Öz:
Hemolytic uremic syndrome (HUS) is a clinical syndrome characterized by the triad of thrombotic microangiopathy, thrombocytopenia, and acute kidney injury. Hemolytic uremic syndrome represents a heterogeneous group of disorders with variable etiologies that result in differences in presentation, management and outcome. In recent years, better understanding of the HUS, especially those due to genetic mutations in the alternative complement pathway have provided an update on the terminology, classification, and treatment of the disease. This review will provide the updated classification of the disease and the current diagnostic and therapeutic approaches on the complement-mediated HUS in addition to STEC-HUS which is the most common cause of the HUS in childhood.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Rosove M. Thrombotic microangiopathies. Semin Arthritis and Rheumatism 2014; 43: 797-805. [CrossRef ]
  • 2. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program 2012; 2012: 617-25.
  • 3. Cataland SR, Wu HM. Atypical hemolytic uremic syndrome and thrombotic thrombocytic purpura: Clinically differentiating the thrombotic microangiopathies. Eur J Intern Med 2013; 24: 486-91. [CrossRef ]
  • 4. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035-50. [CrossRef ]
  • 5. Besbas N, Karpman D, Landau D, et al; European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-31. [CrossRef]
  • 6. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6: 60. [CrossRef ]
  • 7. Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. Worl J Nephrol 2013; 6: 56-76. [CrossRef ]
  • 8. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2015; Apr 11. [Epub ahead of print] [CrossRef ]
  • 9. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin producing Escherichia coli and hemolytic uremic syndrome. Lancet 2005; 365: 1073-86.
  • 10. Ruggenenti P, Remuzzi G. A German outbreak of hemolytic uremic syndrome. Lancet 2011; 378: 1057-8. [CrossRef ]
  • 11. Robert Koch Institut. Final presentation and evaluation of epidemiological findings in the EHEC O104:H+ outbreak Germany 2011. September 2011. Available from: http://www.rki.de/EN/Home/EHECfinalreport.pdf. Eri- şim tarihi: Erişim tarihi: 03.03.2015
  • 12. Elliott EJ, Robins-Browne RM, O’Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 8: 125-31. [CrossRef ]
  • 13. Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemolytic Uremic Syndrome after an Escherichia coli O111 Outbreak. Arch Intern Med 2010; 170: 1656-63. [CrossRef ]
  • 14. Tozzi AE, Caprioli A, Minelli F, et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. Emerg Infect Dis 2003; 9: 106-8. [CrossRef ]
  • 15. Bhimma R, Rollins NC, Coovadia HM, Adhikari M. Postdysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol 1997; 11: 560-4. [CrossRef ]
  • 16. Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272: 1349-53. [CrossRef ]
  • 17. Vaillant V, Espié E, de Valk H, et al. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J 2009; 28: 650-3. [CrossRef ]
  • 18. Ulinski T, Lervat C, Ranchin B, Gillet Y, Floret D, Cochat P. Neonatal hemolytic uremic syndrome after motherto-child transmission of Escherichia coli O157. Pediatr Nephrol 2005; 20: 1334-5. [CrossRef ]
  • 19. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-33. [CrossRef ]
  • 20. Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8 :658-69. [CrossRef ]
  • 21. McLaine PN, Rowe PC, Orrbine E. Experiences with HUS in Canada: what have we learned about childhood HUS in Canada? Kidney Int Suppl 2009; 112: S25-8. [CrossRef ]
  • 22. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186: 493-500. [CrossRef ]
  • 23. Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-15. [CrossRef ]
  • 24. Johnson S, Taylor CM. Hemolytic uremic syndromes. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. 6th ed. Berlin-Heidelberg: Springer-Verlag; 2009. p. 1155-80. [CrossRef ]
  • 25. de Buys Roessingh AS, de Lagausie P, Baudoin V, Loirat C, Aigrain Y. Gastrointestinal complications of postdiarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 2007; 17: 328-34. [CrossRef ]
  • 26. Askiti V, Hendrickson K, Fish AJ, Braunlin E, Sinaiko AR. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol 2004; 19: 345-8. [CrossRef ]
  • 27. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23: 1749-60. [CrossRef ]
  • 28. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-3. [CrossRef ]
  • 29. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associate haemolytic uraemic syndrome. A systemic review, meta-analysis and metaregression. JAMA 2003; 290: 1360–70. [CrossRef ]
  • 30. Sellier-Leclerc AL, Fremeaux-Bacchi V, Macher MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-400. [CrossRef ]
  • 31. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-59. [CrossRef ]
  • 32. Geerdink LM, Westra D, van Wijk JA, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27: 1283-91. [CrossRef ]
  • 33. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005: 16: 555-63. [CrossRef ]
  • 34. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010; 25: 2431-42. [CrossRef]
  • 35. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-79. [CrossRef ]
  • 36. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008; 23: 1957-72. [CrossRef ]
  • 37. Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 2150-5. [CrossRef ]
  • 38. Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948-52. [CrossRef ]
  • 39. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012; 119: 4182-91. [CrossRef ]
  • 40. Roumenina LT, Jablonski M, Hue C, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114: 2837-45. [CrossRef ]
  • 41. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-57. [CrossRef ]
  • 42. Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180-7. [CrossRef]
  • 43. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87. [CrossRef ]
  • 44. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-81. [CrossRef ]
  • 45. Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148: 37-47. [CrossRef ]
  • 46. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18: 1095-101.[CrossRef ]
APA CANPOLAT N (2015). Hemolitik üremik sendrom. Türk Pediatri Arşivi, 50(2), 73 - 82.
Chicago CANPOLAT NUR Hemolitik üremik sendrom. Türk Pediatri Arşivi 50, no.2 (2015): 73 - 82.
MLA CANPOLAT NUR Hemolitik üremik sendrom. Türk Pediatri Arşivi, vol.50, no.2, 2015, ss.73 - 82.
AMA CANPOLAT N Hemolitik üremik sendrom. Türk Pediatri Arşivi. 2015; 50(2): 73 - 82.
Vancouver CANPOLAT N Hemolitik üremik sendrom. Türk Pediatri Arşivi. 2015; 50(2): 73 - 82.
IEEE CANPOLAT N "Hemolitik üremik sendrom." Türk Pediatri Arşivi, 50, ss.73 - 82, 2015.
ISNAD CANPOLAT, NUR. "Hemolitik üremik sendrom". Türk Pediatri Arşivi 50/2 (2015), 73-82.